Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$7.81 USD
+0.35 (4.69%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $7.80 -0.01 (-0.13%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Terns Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -90.21 | -60.35 | -50.16 | -40.57 | -68.82 |
Depreciation/Amortization & Depletion | -4.15 | 1.11 | 1.39 | 0.43 | 0.16 |
Net Change from Assets/Liabilities | 1.29 | -1.04 | -1.43 | 5.06 | 1.87 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 25.68 | 11.16 | 8.37 | 5.27 | 0.57 |
Net Cash From Operating Activities | -67.39 | -49.11 | -41.83 | -29.81 | -66.22 |
Property & Equipment | -0.05 | -0.28 | -0.34 | -0.58 | -0.90 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -37.94 | -22.00 | -119.36 | 7.28 | -2.96 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -37.99 | -22.27 | -119.70 | 6.69 | -3.86 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 42.30 | 167.50 | 0.91 | 69.50 | 0.03 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 136.20 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 16.88 | 0.06 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.34 | -0.40 | -2.72 | -0.86 | -0.02 |
Net Cash from Financing Activities | 41.95 | 167.10 | 134.39 | 85.52 | 0.06 |
Effect of Exchange Rate Changes | 0.12 | -0.18 | -0.03 | 0.08 | -0.13 |
Net Change In Cash & Equivalents | -63.31 | 95.54 | -27.16 | 62.48 | -70.15 |
Cash at Beginning of Period | 143.24 | 47.70 | 74.85 | 12.38 | 82.52 |
Cash at End of Period | 79.93 | 143.24 | 47.70 | 74.85 | 12.38 |
Diluted Net EPS | -1.27 | -1.67 | -2.21 | -102.93 | NA |
Fiscal Year End for Terns Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -45.11 | -22.37 | -90.21 | -69.19 | -39.42 |
Depreciation/Amortization & Depletion | 0.48 | -0.12 | -4.15 | -2.87 | -1.34 |
Net Change from Assets/Liabilities | -1.94 | -4.36 | 1.29 | 1.64 | 5.16 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.59 | 4.06 | 25.68 | 22.35 | 8.24 |
Net Cash From Operating Activities | -38.98 | -22.80 | -67.39 | -48.07 | -27.38 |
Property & Equipment | -0.04 | -0.03 | -0.05 | -0.01 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 50.23 | 8.03 | -37.94 | -85.21 | -62.91 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 50.19 | 8.00 | -37.99 | -85.22 | -62.91 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.40 | 0.00 | 42.30 | 0.51 | 0.49 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 27.92 | 27.92 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.34 | -0.34 | -0.34 |
Net Cash from Financing Activities | 0.40 | 0.00 | 41.95 | 28.09 | 28.07 |
Effect of Exchange Rate Changes | -0.04 | -0.03 | 0.12 | -0.14 | -0.10 |
Net Change In Cash & Equivalents | 11.57 | -14.83 | -63.31 | -105.34 | -62.32 |
Cash at Beginning of Period | 79.93 | 79.93 | 143.24 | 143.24 | 143.24 |
Cash at End of Period | 91.50 | 65.10 | 79.93 | 37.89 | 80.92 |
Diluted Net EPS | -0.31 | -0.30 | -0.29 | -0.42 | -0.25 |